CRH (CRH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Record 2025 financial results: revenues up 5% to $37.4B, net income up 8% to $3.8B, Adjusted EBITDA up 11% to $7.7B, and diluted EPS up 10% to $5.51.
Total Shareholder Return for 2025 was 36.8%, with share price rising from $92.52 to $124.80.
$4.1B invested in 38 acquisitions, including $2.1B for Eco Material Technologies, and $1.7B in growth capex.
Continued long-term dividend growth policy; 2025 dividend increased 6% to $1.48 per share.
Announced intention to delist from LSE and cancel legacy Preference Shares, subject to shareholder approval.
Voting matters and shareholder proposals
12 proposals at 2026 AGM: re-election of 12 directors, advisory vote on executive compensation, auditor appointment and compensation, renewal of authorities to issue shares, repurchase shares, re-issue treasury shares, and several proposals related to Preference Share cancellations and amendments to Articles.
Preference Share cancellations involve court-approved schemes, capital reduction, and amendments to Articles.
Shareholders to vote on removal of director qualification shareholding requirement.
Board of directors and corporate governance
Board comprises 12 directors, 92% independent, with diverse skills in industry, finance, M&A, governance, and sustainability.
Annual board and committee evaluations, with external facilitation in 2025.
Board succession planning and refreshment are ongoing priorities.
Five standing committees: Audit, Compensation, Nomination & Corporate Governance, Acquisitions/Divestments & Finance, and Safety/Environment/Social Responsibility.
Latest events from CRH
- Definitive proxy statement filed for shareholder voting under SEC regulations.CRH
Proxy filing27 Mar 2026 - Record financials, capital structure simplification, and key governance proposals for 2026 AGM.CRH
Proxy Filing13 Mar 2026 - Delisting and preference share cancellations aim to simplify capital structure and cut costs.CRH
Proxy Filing13 Mar 2026 - Record 2025 financials, double-digit EBITDA growth, and strong 2026 outlook on infrastructure demand.CRH
Q4 202519 Feb 2026 - Q2 net income up 8%, EBITDA up 12%, margins expanded, and FY24 guidance raised.CRH
H1 20242 Feb 2026 - Q3 saw strong sales, margin gains, and M&A, with a positive outlook reaffirmed.CRH
Q3 2024 TU16 Jan 2026 - Double-digit profit growth and margin expansion achieved, with strong 2025 outlook.CRH
H2 20247 Jan 2026 - Record Q3, raised FY25 EBITDA guidance, and strong outlook driven by demand and acquisitions.CRH
Q3 2025 TU21 Dec 2025 - Record financials, new equity plan, governance updates, and strong ESG progress headline the proxy.CRH
Proxy Filing2 Dec 2025